Premium
Abrogation of cell‐mediated immunity by hyperimmune alloantiserum: Mechanisms and correlation with allograft enhancement
Author(s) -
Cohen James M.,
Yang Stringner S.,
Law Lloyd W.
Publication year - 1974
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910130405
Subject(s) - effector , cytotoxicity , antigen , immunity , antibody , c57bl/6 , neoplasm , cell , chemistry , blocking (statistics) , microbiology and biotechnology , immunology , biology , immune system , in vitro , biochemistry , genetics , statistics , mathematics
Alloantiserum blocking of cell‐mediated immunity as measured by a 51 chromium release cell‐mediated cytotoxicity assay has been characterized and correlated with immunological enhancement of tumor allografts across H‐2 barriers in mice. Alloantiserum blocking was found to be immunologically specific, quantitative, and highly reproducible. Cytotoxicity could be blocked by adding alloantiserum directly into the reaction mixture or by pretreating the target cells with alloantiserum. Effector cells could also be specifically blocked by pretreatment with alloantigens or with a fraction isolated from a mixture of alloantiserum and ascitic fluid containing alloantibody. Pretreatment of effector cells with alloantibody alone had no blocking effect. Upon purification, this fraction dissociated into IgG and a small molecular species with some biochemical and antigenic properties analogous to H‐2 fragments. These observations are consistent with the hypothesis that the isolated fraction may have been an antigen‐antibody complex consisting of alloantibody and H‐2 alloantigen. In addition, blocking was shown to be surmountable under certain conditions by increasing the number of effector cells. The implications and mechanism of alloantiserum blocking and its relationship to immunological enhancement are discussed.